26819-11-4

Basic information

• Product Name: BenzaMide, N-ethyl-3-nitro-
• Synonyms: BenzaMide, N-ethyl-3-nitro-
• CAS NO: 26819-11-4
• Molecular Formula: C₉H₁₀N₂O₃
• Molecular Weight: 194.1873
• Mol File: 26819-11-4.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: BenzaMide, N-ethyl-3-nitro-(CAS DataBase Reference)
• NIST Chemistry Reference: BenzaMide, N-ethyl-3-nitro-(26819-11-4)
• EPA Substance Registry System: BenzaMide, N-ethyl-3-nitro-(26819-11-4)

Safety Data

• Hazardous Substances Data: 26819-11-4(Hazardous Substances Data)

Usage

General Description

Benzamide, N-ethyl-3-nitro- is a chemical compound with the molecular formula C9H10N2O3. It is a yellow crystalline solid that is insoluble in water but soluble in organic solvents. Benzamide, N-ethyl-3-nitro- is often used as an intermediate in the synthesis of other chemicals, and it is also known to have antifungal and antibacterial properties. Although it has not been extensively studied for its potential uses, research suggests that it could have applications in the pharmaceutical and agricultural industries. Additionally, it is important to handle this compound with caution, as it may be harmful if swallowed, inhaled, or absorbed through the skin.

Upstream product

• 75-04-7 ethylamine 
• 121-90-4 m-nitrobenzoic acid chloride 
• 557-66-4 ethanamine hydrochloride 

Downstream Products

• 81882-77-1 3-amino-N-ethylbenzamide 
• 59476-49-2 N-(3-nitrobenzoyl)-N-ethyl-nitramin 

Relevant articles and documents

Selectivity, ligand deconstruction, and cellular activity analysis of a BPTF bromodomain inhibitor

Bromodomain and PHD finger containing protein transcription factor (BPTF) is an epigenetic protein involved in chromatin remodelling and is a potential anticancer target. The BPTF bromodomain has one reported small molecule inhibitor (AU1, rac-1). Here, advances made on the structure-activity relationship of a BPTF bromodomain ligand are reported using a combination of experimental and molecular dynamics simulations leading to the active enatiomer (S)-1. Additionally, a ligand deconstruction analysis was conducted to characterize important pharmacophores for engaging the BPTF bromodomain. These studies have been enabled by a protein-based fluorine NMR approach, highlighting the versatility of the method for selectivity, ligand deconstruction, and ligand binding. To enable future analysis of biological activity, cell growth analyses in a panel of cancer cell lines were carried out using CRISPR-Cas9 and (S)-1 to identify cell-based model systems that are sensitive to BPTF inhibition.

11a-Methano-TXA compounds

The present invention provides novel 11a-methano-TXA compounds and intermediates and processs for their preparation. Further provided are methods for using these novel TXA analogs as inhibitors of thromboxane synthetase, rendering these analogs useful for a variety of pharmacological purposes. These pharmacological uses include anti-inflammatory, anti-thromobitc, and anti-asthma indications.